Misplaced Pages

Cendakimab (RPC4046; ABT 308; CC-93538) is a monoclonal antibody against interleukin 13. It is developed by Bristol Myers Squibb for eosinophilic esophagitis.

References

1. "Pharmaceutical Research & Development Pipeline - Bristol Myers Squibb". www.bms.com. Retrieved 4 December 2023.
2. Syverson EP, Hait E (April 2022). "Update on Emerging Pharmacologic Therapies for Patients With Eosinophilic Esophagitis". Gastroenterology & Hepatology. 18 (4): 207–212. ISSN 1554-7914. PMC 9053490. PMID 35505944.
3. Caldwell J, Ballaban A, Li J, Maddux R, Harris S, Rothenberg M (February 2023). "Anti–IL-13 (cendakimab) administration improves esophageal gene expression in eosinophilic esophagitis". Journal of Allergy and Clinical Immunology. 151 (2): AB215. doi:10.1016/j.jaci.2022.12.670. S2CID 256589074.
4. Hirano I, Collins MH, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer AM, et al. (February 2019). "RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis". Gastroenterology. 156 (3): 592–603.e10. doi:10.1053/j.gastro.2018.10.051. PMID 30395812.

• Medicine

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Drugs developed by Bristol Myers Squibb
• Anti-interleukin monoclonal antibodies
• Pharmacology stubs